Compare Novartis AG (NVS) vs Schlumberger NV (SLB) Price & Performance

Novartis (NVS) stock is trading at $137.7, down 13.93% over 24 hours following negative clinical trial news. The technical outlook is bearish with support at $133 and resistance at $138. Fundamentally, the company maintains strong profitability with a 22.5% net income margin and $56.67B revenue in 2025, though recent pipeline setbacks have pressured sentiment. Analyst consensus is mixed with 24% buy ratings but 68% hold, reflecting caution amid growth uncertainties.

The investment outlook is clouded by recent trial failures, but Novartis' solid cash flow and reiterated 5-6% revenue growth guidance through 2030 provide a foundation. Key risks include pipeline execution and competitive threats, while institutional ownership trends will be critical to watch for stability signals. The stock offers value if management can navigate current headwinds effectively.

SLB trades at $57.10, down 0.71% on the day, with strong analyst support (85% buy ratings) and a $63.50 consensus price target. The stock shows bullish technical momentum with recent earnings beats and a strategic $3.4 billion acquisition of Kelvion to expand into data center cooling technology. Revenue remains stable at $35.7 billion (2025) with solid profitability metrics including 8.53% net margin and 13.37% ROE.

The outlook remains positive with diversification into high-growth data center markets, though risks include oil price volatility and execution challenges from recent acquisitions. Current valuation at 27.85 P/E appears reasonable given growth initiatives, supporting a constructive view for long-term investors despite near-term market fluctuations.